Cingulate Inc (CING) - Total Assets
Based on the latest financial reports, Cingulate Inc (CING) holds total assets worth $15.07 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cingulate Inc - Total Assets Trend (2019–2025)
This chart illustrates how Cingulate Inc's total assets have evolved over time, based on quarterly financial data. Also see Cingulate Inc market cap and net worth for the company's overall valuation and market capitalisation.
Cingulate Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cingulate Inc's total assets of $15.07 Million consist of 79.3% current assets and 20.7% non-current assets. Review Cingulate Inc (CING) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.7% |
| Accounts Receivable | $8.01K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Cingulate Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cingulate Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cingulate Inc's current assets represent 79.3% of total assets in 2025, an increase from 18.5% in 2019.
- Cash Position: Cash and equivalents constituted 72.7% of total assets in 2025, up from 7.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Cingulate Inc Competitors by Total Assets
Key competitors of Cingulate Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Cingulate Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 2.55 | 0.53 |
| Quick Ratio | 1.16 | 2.55 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.64 Million | $7.69 Million | $-1.57 Million |
Cingulate Inc - Advanced Valuation Insights
This section examines the relationship between Cingulate Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.73 |
| Latest Market Cap to Assets Ratio | 4.19 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | $15.07 Million |
| Market Capitalization | $63.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cingulate Inc's assets at a significant premium (4.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Cingulate Inc's assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cingulate Inc (2019–2025)
The table below shows the annual total assets of Cingulate Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $15.07 Million | +1.40% |
| 2024-12-31 | $14.86 Million | +325.74% |
| 2023-12-31 | $3.49 Million | -69.39% |
| 2022-12-31 | $11.41 Million | -50.17% |
| 2021-12-31 | $22.89 Million | +295.44% |
| 2020-12-31 | $5.79 Million | +9.60% |
| 2019-12-31 | $5.28 Million | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more